Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time - A report of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

Bone Marrow Transplantation

Volumn 17, Issue 1, 1996, Pages 13-18

  Frassoni, F ^b   Labopin, M ^b   Gluckman, E ^b   Prentice, H G ^b   Vernant, J P ^b   Zwaan, F ^b   Granena, A ^b   Gahrton, G ^b   De Witte, T ^b   Gratwohl, A ^b   Reiffers, J ^b   Gorin, N C ^a  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b NONE

Author keywords

Acute leukemia; Allogeneic BMT; EBMT; Improvement

Indexed keywords

CYCLOSPORIN A; METHOTREXATE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CHILD; EUROPE; FEMALE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; INCIDENCE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RELAPSE; SIBLING; SURVIVAL; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT VS HOST DISEASE; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0030061801     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Bortin MM, Horowitz MM, Rimm AA. Increasing utilization of allogeneic bone marrow transplantation. III: results of the 1988-90 survey. Ann Intern Med 1992; 116: 505-512.
2. Gratwohl A, Hermans J, Barren AJ et al. Allogeneic bone marrow transplantation for leukaemia in Europe. Lancet 1988; 1: 1379-1382.
3. Bortin MM, Horowitz MM, Gale RP et al. Changing trends in allogeneic bone marrow transplantation for leukemia in the 1980s. JAMA 1992; 268: 607-612.
4. Appelbaum FR, Fisher LD, Thomas ED and the Seattle Marrow Transplant Team. Chemotherapy vs marrow transplantation for adults with acute nonlymphocytic leukemia: a five-year follow-up. Blood 1988; 72: 179-184.
5. Mayer RB. Allogeneic transplantation versus intensive chemotherapy in first remission acute leukemia: Is there a 'best choice'? Editorial. J Clin Oncol 1988; 10: 1532-1535.
6. Horowitz MM, Messerer D, Hoeltzer D et al. Chemotherapy compared with bone marrow transplantation for adults with acute lymphoblastic leukemia in first remission. Ann Intern Med 1991; 115: 13-18.
7. Cassileth PA, Lynch E, Hines JD et al. Varying intensity of postremission therapy in acute leukemia. Blood 1992; 79: 1924-1930.
8. Wolff SN, Herzig RH, Fay JW et al. High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: long term follow-up and results. J Clin Oncol 1989; 7: 1260-1267.
9. Hoelzer D, Thiel E, Loeffler H et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 1988; 71: 123-131.
10. Gorin NC, Labopin M, Meloni G et al. Autologous bone marrow transplantation for acute myeloblastic leukemia in Europe: further evidence of the role of marrow purging by mafosfamide. Leukemia 1991; 5: 896-904.
11. Mandelli F, Labopin M, Granena A et al. European survey of the role of bone marrow transplantation in acute promyelocytic leukemia (M3). Bone Marrow Transplant 1994; 14: 293-298.
12. Chao N, Stein AS, Long GD et al. Busulfan/etoposide - initial experience with a new preparatory regimen for autologous bone marrow transplantation in patients with acute non-lymphoblastic leukemia. Blood 1993; 81: 319-323.
13. Zittoun R, Mandelli F, Willemze R et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. New Eng J Med 1995; 331: 217-223.
14. Kaplan EI, Meier P. Non-parametric estimation for incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
15. Cox DR. Regression models and life tables. JR Stat Soc Ser B 1972; 34 187-220.
16. Clift RA, Appelbaum FR, Thomas ED. Treatment of chronic myeloid leukemia by bone marrow transplantation. Blood 1993; 82; 1954-1956.
17. Prentice HG, Gluckman E, Powles RL et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogcneic bone marrow transplantation. Lancet 1994; 343: 749-757.
18. Ringden O, Horowitz MM, Sondel P et al. Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia? Blood 1993; 81: 1094-1101.
19. Storb R, Deeg HJ, Pepe M et al. Methotrexate and cyclosporin versus cyclosporin alone for prophylaxis of graft-versus-host disease in patients given HLA identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 1989; 73: 1729-1734.
20. Rivera GK, Pinkel D, Simone JV et al Treatment of acute lymphoblastic leukemia. 30 years' experience at St Jude Children's Research Hospital. New Engl J Med 1993; 329: 1289-1295.
21. Burnett AK, Goldstone AH, Stevens RF et al. The role of BMT in addition to intensive chemotherapy in AML in first CR: results of the MRC AML-10 trial. Blood 1994; 84: (suppl 1) 252a (abstr.).
22. Bloomfield CD, Lawrence D, Arthur DC et al. Curative impact of intensification with high-dose cytarabine in acute myeloid leukemia (AML) varies by cytogenetic group. Blood 1994; 84: (suppl 1) 111a (Abstr.).
23. Lowenberg B. Post-remission treatment of acute myelogenous leukemia. New Engl J Med 1995; 331: 260-262.